SCHEMBL2837462

SCHEMBL2837462

C=CCCCCCOC(C)=O

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.56
MAPT P10636 3/20 0.56
USP2 O75604 3/20 0.56
LMNA P02545 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
RECQL P46063 1/20 0.56
ALDH1A1 P00352 5/20 0.54
HPGD P15428 2/20 0.54
LPAR3 Q9UBY5 2/20 0.50
LPAR2 Q9HBW0 1/20 0.50
TSHR P16473 5/20 0.48
ABCC4 O15439 1/20 0.47
APOBEC3A P31941 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
PTGS2 P35354 1/20 0.40
HCAR2 Q8TDS4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL592903 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL2837141 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL2839053 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL8463541 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL2841007 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL2836294 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL585734 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL2838417 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL816892 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2
SCHEMBL28416989 1.00 CYP3A4 (0.56) CYP3A4MAPTUSP2LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3129347-A1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES California Institute of Technology (US) 2017-02-15 EP claimed
WO-2015157736-A1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2015-10-15 WO claimed
US-20150284313-A1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-08 US claimed
CN-115515989-B Modified ethylene-vinyl alcohol resin and gas barrier material 三菱化学株式会社 2025-05-27 CN disclosed
EP-4502049-A1 MODIFIED ETHYLENE-VINYL ALCOHOL COPOLYMER COMPOSITION, PELLETS, MULTILAYER STRUCTURE, METHOD FOR PRODUCING MODIFIED ETHYLENE-VINYL ALCOHOL COPOLYMER COMPOSITION, AND METHOD FOR PRODUCING MULTILAYER STRUCTURE Mitsubishi Chemical Corporation (JP) 2025-02-05 EP disclosed
US-20240400727-A1 MODIFIED ETHYLENE-VINYL ALCOHOL COPOLYMER COMPOSITION, PELLETS, MULTILAYER STRUCTURE, METHOD FOR PRODUCING MODIFIED ETHYLENE-VINYL ALCOHOL COPOLYMER COMPOSITION, AND METHOD FOR PRODUCING MULTILAYER STRUCTURE MITSUBISHI CHEMICAL CORPORATION (JP) 2024-12-05 US disclosed
CN-118804948-A Modified ethylene-vinyl alcohol copolymer composition, pellet, multilayer structure, method for producing modified ethylene-vinyl alcohol copolymer composition, and method for producing multilayer structure 三菱化学株式会社 2024-10-18 CN disclosed
EP-4438641-A1 MODIFIED ETHYLENE-VINYL ALCOHOL RESIN COMPOSITION, GAS BARRIER MATERIAL, AND STRETCHED FILM Mitsubishi Chemical Corporation (JP) 2024-10-02 EP disclosed
US-20240287297-A1 MODIFIED ETHYLENE-VINYL ALCOHOL RESIN COMPOSITION, GAS-BARRIER MATERIAL, AND STRETCHED FILM MITSUBISHI CHEMICAL CORPORATION (JP) 2024-08-29 US disclosed
EP-4421100-A1 PROCESS FOR PRODUCTION OF ETHYLENE-VINYL ALCOHOL COPOLYMER AND PRODUCTION METHOD FOR ETHYLENE-VINYL ALCOHOL COPOLYMER Mitsubishi Chemical Corporation (JP) 2024-08-28 EP disclosed
US-20240270886-A1 ETHYLENE-VINYL ALCOHOL COPOLYMER AND PRODUCTIN METHOD FOR ETHYLENE-VINYL ALCOHOL COPOLYMER MITSUBISHI CHEMICAL CORPORATION (JP) 2024-08-15 US disclosed
CN-102123979-A Method for synthesizing terminal olefins from internal olefins by olefin metathesis ELEVANCE RENEWABLE SCIENCES 2011-07-13 CN disclosed
US-20100145086-A1 Synthesis of Terminal Alkenes From Internal Alkenes Via Olefin Metathesis ELEVANCE RENEWABLE SCIENCES, INC. 2010-06-10 US disclosed
EP-2076484-A2 SYNTHESIS OF TERMINAL ALKENES FROM INTERNAL ALKENES VIA OLEFIN METATHESIS Elevance Renewable Sciences, Inc. (US) 2009-07-08 EP disclosed
WO-2008046106-A2 SYNTHESIS OF TERMINAL ALKENES FROM INTERNAL ALKENES VIA OLEFIN METATHESIS ELEVANCE RENEWABLE SCIENCES, INC. (US) 2008-04-17 WO disclosed
US-6610733-B2 Antiestrogen, therapeutic agent for breast cancer CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-08-26 US disclosed
US-20030125571-A1 Optically active chroman and thiochroman derivatives CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-07-03 US disclosed
US-6552068-B1 Having anti-estrogenic activity; for use in therapy CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-04-22 US disclosed
EP-1241167-A1 3-ETHYL-, 3-PROPYL- OR 3-BUTYL-CHROMAN AND -THIOCHROMAN DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-09-18 EP disclosed
EP-1241165-A1 OPTICALLY ACTIVE CHROMAN AND THIOCHROMAN DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125571-A1 Optically active chroman and thiochroman derivatives NR5A1, CYP19A1, SHBG CYP3A4 56/4885MAPT 2959/4885USP2 3858/4885
US-20150284313-A1 REACTIONS IN THE PRESENCE OF RUTHENIUM COMPLEXES DDC, LTC4S, CYCS CYP3A4 31/4885MAPT 4101/4885USP2 3181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.